Case Report of Myelodysplastic Syndrome in a Sickle-Cell Disease Patient Treated with Hydroxyurea and Literature Review

The safety profile of hydroxyurea (HU) in patients with sickle-cell disease (SCD) is relatively well known. However, despite the suspected association of HU with myeloid neoplasms in myeloproliferative neoplasms (MPN), and the publication of sporadic reports of myeloid malignancies in SCD patients t...

Descripción completa

Detalles Bibliográficos
Autores principales: Flevari, Pagona, Voskaridou, Ersi, Galactéros, Frédéric, Cannas, Giovanna, Loko, Gylna, Joseph, Laure, Bartolucci, Pablo, Gellen-Dautremer, Justine, Bernit, Emmanuelle, Charneau, Corine, Habibi, Anoosha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775156/
https://www.ncbi.nlm.nih.gov/pubmed/36551957
http://dx.doi.org/10.3390/biomedicines10123201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775156/
https://www.ncbi.nlm.nih.gov/pubmed/36551957
http://dx.doi.org/10.3390/biomedicines10123201

Ejemplares similares